

PRESIDENTS



CLAUDIO CERCHIONE
ISTITUTO SCIENTIFICO
ROMAGNOLO PER LO
STUDIO DEI TUMORI
DINO AMADORI - IRCCS
ITALY



DAVID W. GREENING
BAKER HEART AND
DIABETES INSTITUTE
LA TROBE UNIVERSITY
AUSTRALIA



GIOVANNI MARTINELLI
ISTITUTO SCIENTIFICO
ROMAGNOLO PER LO
STUDIO DEI TUMORI
DINO AMADORI - IRCCS
ITALY



ANTONIA REALE
MONASH UNIVERSITY
THE ALFRED
AUSTRALIA



ANDREW SPENCER
MONASH UNIVERSITY
THE ALFRED
AUSTRALIA



ANGELO VACCA
UNIVERSITÀ DEGLI STUDI
DI BARI ALDO MORO
ITALY

SCIENTIFIC BOARD


C. CERCHIONE R. RIA
D. W. GREENING A. SPENCER
G. MARTINELLI A. VACCA
A. REALE

SCIENTIFIC SECRETARIAT

C. CERCHIONE A. REALE
D. W. GREENING G. SIMONETTI
A. FRASSANITO A. G. SOLIMANDO
G. MARTINELLI A. SPENCER
A. MELACCIO A. VACCA



PATRONAGE



ORGANIZING SECRETARIAT



1ST JULY 2021

EXTRACELLULAR VESICLES AND THEIR ROLE IN PATIENTS WITH MULTIPLE MYELOMA

10,5 CME/ECM FOR: PHYSICIANS, BIOLOGISTS, BIOMEDICAL LABORATORY TECHNICIANS, NURSES

FREE REGISTRATION

SOHOITALY.IT

@SOHOITALY



info@proeventi.it
www.proeventi.it

IN THE PAST DECADE, THERE HAVE BEEN MAJOR ADVANCES IN THE TREATMENT OF THE BLOOD CANCER MULTIPLE MYELOMA (MM). THE INTRODUCTION OF NOVEL AGENTS SUCH AS IMMUNE-MODIFYING AGENTS (IMiDs), PROTEASOME INHIBITORS, MONOCLONAL ANTIBODIES, WITH OR WITHOUT STEM CELL TRANSPLANTATION, HAS RESULTED IN SIGNIFICANTLY IMPROVED PATIENT SURVIVAL. MEANWHILE, THE INCREASED UNDERSTANDING OF MM TUMOR BIOLOGY HAS PROVIDED A RATIONALE FOR NEW COMBINATIONS OF DRUGS AND RISK-ADAPTED AND INDIVIDUALIZED TREATMENTS TO FURTHER IMPROVE PATIENT MANAGEMENT.

EXTRACELLULAR VESICLES (EVs) ARE CELL-DERIVED MEMBRANOUS PARTICLES THAT MEDIATE CELL-TO-CELL COMMUNICATION BY TRANSFERRING PROTEINS, LIPIDS AND NUCLEIC ACIDS LOCALLY AND THROUGH SYSTEMIC CIRCULATION. EVs ARE ACTIVE REGULATORS IN THE CROSS-TALK BETWEEN MM TUMOUR CELLS AND BONE MARROW MICROENVIRONMENT, WITH THE CAPACITY TO ALTER ANGIOGENESIS, OSTEOCLAST DIFFERENTIATION AND IMMUNOSUPPRESSION, PROMOTING TUMOUR PROGRESSION AND DRUG RESISTANCE. CIRCULATING EVs CONTAINING TUMOUR-SPECIFIC MOLECULAR SIGNATURES (ONCOPROTEINS, RNAs, DNA FRAGMENTS) HAVE POTENTIAL CLINICAL UTILITY AS NEXT-GENERATION LIQUID BIOPSY BIOMARKERS IN CANCER DIAGNOSIS AND MANAGEMENT, WITH THE POTENTIAL TO CHARACTERISE BOTH SPATIAL HETEROGENEITY AND CLONAL EVOLUTION THUS INFORMING NEW MODALITIES FOR DIAGNOSIS, RISK STRATIFICATION, MONITORING AND THERAPEUTIC INTERVENTION IN MM. HOWEVER, THE NANO-SCALE NATURE OF EVs AND THE COMPLEXITY OF BIOFLUIDS PRESENT CHALLENGES THAT NEED TO BE ADDRESSED BEFORE THE POTENTIAL OF EVs AS BIOMARKERS AND THERAPEUTIC TARGETS CAN BE ACHIEVED.

THE ITALIAN SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO ITALY) WAS ESTABLISHED AS A NON-PROFIT ORGANIZATION IN 2019 TO PROMOTE WORLDWIDE RESEARCH (EDUCATION, PREVENTION, PRECLINICAL AND CLINICAL STUDIES AND PATIENT CARE) OF HEMATOLOGIC MALIGNANCIES AND RELATED DISORDERS. IN THIS SCENARIO, SOHO ITALY TOGETHER WITH AUSTRALIAN COLLEAGUES AIM TO BRING TOGETHER INTERNATIONAL EXPERTS TO DISCUSS THE LATEST ADVANCES IN THE PATHOPHYSIOLOGY AND THERAPY OF MM AND TO BETTER UNDERSTAND THE ROLE OF EVs IN PATIENTS WITH MM.



CENTRAL EUROPEAN SUMMER TIME

07.45 WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI

07.50 OPENING REMARKS

C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI

08.00 THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU

08.20 ROLE OF MICROENVIRONMENT IN MM A. VACCA

08.40 IMMUNE SYSTEM IN MM P. NERI

09.00 VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU

09.20 ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO

09.30 LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING

10.20 EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER

10.40 EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI

11.00 EVS AS CANCER DIAGNOSTICS A. MÖLLER

11.20 EV BYSTANDER SIGNALING AND CANCER RESISTANCE P. SAMUEL

11.40 TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG

12.00 ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI

12.10 STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS

12.55 HOW I MANAGE FRONTLINE MM M. V. MATEOS

13.15 HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE

13.35 BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON

13.55 NEW TREATMENT AVENUES IN MM H.C. LEE

14.15 MANAGING INFECTIONS IN MM R. RIA

14.35 ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG

14.55 EVS IN MM BONE DISEASE K. VANDERKERKEN

15.15 EVS IN MM PROGRESSION A. ROCCARO

15.35 MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA

15.55 MM-SMALL EVS, OMICS, PLASMA A. REALE

16.15 ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO

16.25 LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING

16.55 CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM





CANADA MOUNTAIN DAYLIGHT TIME

11.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI

11.50PM (30TH JUNE) OPENING REMARKS

C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI

12.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU

12.20AM ROLE OF MICROENVIRONMENT IN MM A. VACCA

12.40AM IMMUNE SYSTEM IN MM P. NERI

01.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU

01.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO

01.30AM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING

02.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER

02.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI

03.00AM EVS AS CANCER DIAGNOSTICS A. MÖLLER

03.20AM EV BYSTANDER SIGNALING AND CANCER RESISTANCE P. SAMUEL

03.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG

04.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI

04.10AM STUDENT/EGR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS

04.55AM HOW I MANAGE FRONTLINE MM M. V. MATEOS

05.15AM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE

05.35AM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON

05.55AM NEW TREATMENT AVENUES IN MM H.C. LEE

06.15AM MANAGING INFECTIONS IN MM R. RIA

06.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG

06.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN

07.15AM EVS IN MM PROGRESSION A. ROCCARO

07.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA

07.55AM MM-SMALL EVS, OMICS, PLASMA A. REALE

08.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO

08.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING

08.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM





USA CENTRAL STANDARD TIME

12.45AM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI

12.50AM OPENING REMARKS

C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI

01.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU

01.20AM ROLE OF MICROENVIRONMENT IN MM A. VACCA

01.40AM IMMUNE SYSTEM IN MM P. NERI

02.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU

02.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO

02.30AM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING

03.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER

03.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI

04.00AM EVS AS CANCER DIAGNOSTICS A. MÖLLER

04.20AM EV BYSTANDER SIGNALING AND CANCER RESISTANCE P. SAMUEL

04.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG

05.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI

05.10AM STUDENT/EGR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS

05.55AM HOW I MANAGE FRONTLINE MM M. V. MATEOS

06.15AM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE

06.35AM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON

06.55AM NEW TREATMENT AVENUES IN MM H.C. LEE

07.15AM MANAGING INFECTIONS IN MM R. RIA

07.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG

07.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN

08.15AM EVS IN MM PROGRESSION A. ROCCARO

08.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA

08.55AM MM-SMALL EVS, OMICS, PLASMA A. REALE

09.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO

09.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING

09.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM





USA EASTERN STANDARD TIME

01.45AM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI

01.50AM OPENING REMARKS

C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI

02.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU

02.20AM ROLE OF MICROENVIRONMENT IN MM A. VACCA

02.40AM IMMUNE SYSTEM IN MM P. NERI

03.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU

03.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO

03.30AM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING

04.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER

04.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI

05.00AM EVS AS CANCER DIAGNOSTICS A. MÖLLER

05.20AM EV BYSTANDER SIGNALING AND CANCER RESISTANCE P. SAMUEL

05.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG

06.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI

06.10AM STUDENT/EGR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS

06.55AM HOW I MANAGE FRONTLINE MM M. V. MATEOS

07.15AM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE

07.35AM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON

07.55AM NEW TREATMENT AVENUES IN MM H.C. LEE

08.15AM MANAGING INFECTIONS IN MM R. RIA

08.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG

08.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN

09.15AM EVS IN MM PROGRESSION A. ROCCARO

09.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA

09.55AM MM-SMALL EVS, OMICS, PLASMA A. REALE

10.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO

10.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING

10.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM





AUSTRALIAN EASTERN STANDARD TIME

03.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI

03.50PM OPENING REMARKS

C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI

04.00PM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU

04.20PM ROLE OF MICROENVIRONMENT IN MM A. VACCA

04.40PM IMMUNE SYSTEM IN MM P. NERI

05.00PM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU

05.20PM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO

05.30PM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING

06.20PM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER

06.40PM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI

07.00PM EVS AS CANCER DIAGNOSTICS A. MÖLLER

07.20PM EV BYSTANDER SIGNALING AND CANCER RESISTANCE P. SAMUEL

07.40PM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG

08.00PM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI

08.10PM STUDENT/EGR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS

08.55PM HOW I MANAGE FRONTLINE MM M. V. MATEOS

09.15PM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE

09.35PM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON

09.55PM NEW TREATMENT AVENUES IN MM H.C. LEE

10.15PM MANAGING INFECTIONS IN MM R. RIA

10.35PM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG

10.55PM EVS IN MM BONE DISEASE K. VANDERKERKEN

11.15PM EVS IN MM PROGRESSION A. ROCCARO

11.35PM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA

11.55PM MM-SMALL EVS, OMICS, PLASMA A. REALE

12.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO

12.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING

12.55AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM





NEW ZEALAND STANDARD TIME

05.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI

05.50PM OPENING REMARKS

C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI

06.00PM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION J.L. HAROUSSEAU

06.20PM ROLE OF MICROENVIRONMENT IN MM A. VACCA

06.40PM IMMUNE SYSTEM IN MM P. NERI

07.00PM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM I. SAVVIDOU

07.20PM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA A.G. SOLIMANDO

07.30PM LECTURE LIQUID BIOPSY IN MM A. SPENCER

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING

08.20PM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE K. WITWER

08.40PM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE A. RAI

09.00PM EVS AS CANCER DIAGNOSTICS A. MÖLLER

09.20PM EV BYSTANDER SIGNALING AND CANCER RESISTANCE P. SAMUEL

09.40PM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS B. SUNG

10.00PM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA A. FAINI

10.10PM STUDENT/EGR NETWORK ON EVS (SNEV), OVERVIEW A. NASIRI KENARI

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS

10.55PM HOW I MANAGE FRONTLINE MM M. V. MATEOS

11.15PM HOW I MANAGE RELAPSED/REFRACTORY MM C. CERCHIONE

11.35PM BIOLOGICALLY BASED THERAPIES FOR MM K.C. ANDERSON

11.55PM NEW TREATMENT AVENUES IN MM H.C. LEE

12.15AM MANAGING INFECTIONS IN MM R. RIA

12.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS Z. KOZICH

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG

12.55AM EVS IN MM BONE DISEASE K. VANDERKERKEN

01.15AM EVS IN MM PROGRESSION A. ROCCARO

01.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE I. SALTARELLA

01.55AM MM-SMALL EVS, OMICS, PLASMA A. REALE

02.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT E. IACCINO

02.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY D. W. GREENING

02.55AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

